ACB $6.920 (-1.56%)

ACNNF $0.060 (-13.92%)

AERO $3.210 (0%)

ALEAF $0.226 (-0.62%)

AMMJ $0.100 (-0.1%)

APHA $15.380 (0%)

ARNA $61.410 (-2.35%)

ATT:CNX $0.080 (0%)

ATTBF $0.004 (-9.09%)

AUSA:CNX $0.170 (-5.56%)

AUSAF $0.141 (-5.32%)

AVXL $17.760 (1.37%)

BAMM:CNX $0.490 (-1.01%)

BBM:CNX $0.085 (0%)

BBRRF $0.065 (-2.26%)

BE:CNX $0.005 (0%)

BIO:CNX $0.040 (-5.88%)

BLEVF $0.003 (0%)

BLIS:CNX $0.315 (0%)

BLO:CNX $0.720 (2.86%)

BLOZF $0.582 (2.61%)

BUDZ $0.296 (-0.8%)

CADMF $0.114 (-9.88%)

CALI:CNX $0.065 (-7.14%)

CANN $0.386 (-4.64%)

CARA $12.720 (-3.34%)

CBWTF $0.171 (0.29%)

CGC $13.200 (-1.12%)

CGRW $0.071 (-8.32%)

CHOO:CNX $0.060 (-7.69%)

CHOOF $0.049 (1.67%)

CNBX $0.140 (0.14%)

CNGGF $0.210 (1.18%)

CODI $29.860 (-0.8%)

CPMD $0.031 (-10.57%)

CRBP $1.020 (0%)

CRON $5.360 (-2.19%)

CROP:CNX $0.015 (0%)

CRXPF $0.027 (0%)

CSI:CNX $0.140 (-9.68%)

CURR $0.590 (-15.65%)

CVSI $0.236 (-4.92%)

DIGP $0.035 (17.28%)

EAT:CNX $0.120 (0%)

EEVVF $0.147 (-1.28%)

EMHTF $0.088 (8.02%)

EPWCF $0.330 (-4.01%)

EVIO $0.001 (5.56%)

FFRMF $0.008 (-59.5%)

FFT:CNX $0.040 (0%)

FNNZF $0.054 (3.8%)

GNBT $0.160 (-4%)

GRIN:CNX $0.145 (0%)

GRWG $22.100 (0.87%)

GTBIF $22.850 (-3.67%)

GTII:CNX $28.300 (-3.9%)

GWPH $218.960 (0%)

HEXO $1.690 (-2.31%)

HHPHF $0.111 (-13.8%)

HLSPY $0.363 (0%)

HMLSF $5.934 (-0.78%)

HMPPF $0.498 (0%)

HRVOF $0.056 (-6.5%)

HSTRF $0.210 (-4.15%)

HUGE:CNX $1.770 (-2.21%)

IAN:CNX $0.215 (-6.52%)

IGC $1.460 (0%)

IGXT $0.606 (6.32%)

IIPR $240.820 (0.74%)

INQD $0.016 (-6.98%)

IONC:CNX $0.090 (-5.26%)

IONKF $0.070 (-9.26%)

ISOL:CNX $0.035 (0%)

ISOLF $0.001 (0%)

ITHUF $0.175 (-5.56%)

KALTF $0.210 (0%)

KHRNF $0.215 (-5.16%)

KSHB $0.695 (0%)

LHS:CNX $1.470 (0%)

LHSIF $1.145 (0%)

LXX:CNX $8.400 (0%)

MCIG $0.028 (0%)

MEDIF $0.205 (-5.6%)

MJ:CNX $0.245 (-3.92%)

MJNA $0.025 (-2.71%)

MNTR $0.104 (0.19%)

MYM:CNX $0.140 (0%)

MYMMF $0.106 (0%)

NCNNF $0.058 (0%)

NDVAF $0.355 (2.04%)

NGW:CNX $0.415 (-3.49%)

NRXCF $0.069 (0%)

NSPDF $0.032 (14.7%)

NVTQF $0.829 (8.8%)

NWKRF $0.424 (0%)

NXGWF $0.340 (-1.51%)

NXTTF $0.092 (3.49%)

OH:CNX $5.330 (0%)

ORHOF $4.050 (0%)

PHCG $0.300 (-3.26%)

PHVAF $0.038 (0%)

PILL:CNX $0.700 (0%)

PKG:CNX $0.095 (-5%)

PLPRF $0.357 (0%)

PLUS:CNX $0.440 (0%)

PMCB $3.010 (-0.99%)

PNPL $0.005 (0%)

PRCNF $0.003 (0%)

PTNYF $0.081 (2.66%)

QCA:CNX $0.170 (6.25%)

RDDTF $0.044 (-5.15%)

RLLVF $0.012 (0%)

RMHB $0.005 (0%)

RQB:CNX $0.005 (0%)

RQHTF $0.936 (5.3%)

SLNG:CNX $0.165 (0%)

SMG $148.290 (-0.04%)

SNN:CNX $0.155 (0%)

SOL:CNX $3.290 (-3.24%)

SOLCF $2.700 (-2.03%)

SPLIF $0.092 (-3.68%)

SPRWF $0.268 (0%)

SRNA $0.055 (-4.72%)

STEM:CNX $0.290 (0%)

STMH $0.228 (-2.13%)

SUN:CNX $0.150 (0%)

TBPMF $0.186 (-2.1%)

TCAN:CNX $0.700 (-2.78%)

TCNAF $0.570 (0%)

TER:CNX $7.160 (-2.45%)

TGEN $1.760 (-0.06%)

TGIF:CNX $0.080 (6.67%)

TGIFF $0.064 (9.28%)

THC:CNX $0.090 (0%)

THCBF $0.074 (1.51%)

TLRY $10.070 (-1.66%)

TOKI:CNX $0.020 (0%)

TRLFF $0.198 (0.46%)

TRSSF $5.790 (-3.12%)

VIDA:CNX $0.055 (0%)

VIN:CNX $0.105 (5%)

VPRB $0.045 (8.24%)

VRT:CNX $0.450 (0%)

VRTHF $0.170 (275.83%)

VVCIF $0.071 (2.82%)

WAYL:CNX $0.740 (0%)

WLDFF $0.140 (0%)

XXII $2.890 (-0.34%)

ZDPY $0.865 (-1.69%)

ZYNE $3.900 (-3.94%)

Back

5 Major Catalysts On The Horizon That Could Propel Tilray To New Levels

Aug 6, 2021 • 7:33 AM EDT
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Tilray (TSX: TLRY) (Nasdaq: TLRY) made a splash in Canada’s cannabis 2.0 market with the launch of a medical cannabis infused product line. The types of products that are being sold by the global cannabis company include tetrahydrocannabinol (THC) and cannabidiol (CBD) infused chocolates and gummies. 

During the last year, the global cannabis company has been a beneficiary of Canada’s cannabis 2.0 market. Prior to the launch of medical cannabis infused products, Tilray was selling dried premium cannabis flower, concentrates, vapes, and pre-rolls. We expect the company’s cannabis infused products to help the business.  

2021 has been a period of growth for Tilray and the business is considered to be a global pioneer in medical cannabis research, cultivation, and production. Since inception, Tilray has highly focused on Canada’s medical cannabis market and the business remains committed to bringing products that improve patient wellbeing to market.

The Aphria and Tilray Merger is Starting to Payoff

For several years, Tilray has been highly focused on the international cannabis market and has evolved into a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the US, Europe, Australia, and Latin America. 

A few months ago, Tilray and Aphria completed a mega-merger and we believe the combined company is positioned to be a global cannabis leader. The combined company is levered to some of the most attractive markets in the world and we are especially favorable on how its positioned to capitalize on the US and European Union (EU).

We consider the US assets that are owned by the combined company to be one of the most attractive aspects of the merger. Before the merger was announced, Aphria acquired SweetWater Brewing Company which is a leading craft brewery brand in the US. We believe the transaction includes attractive distribution and production assets that could be converted to the production of cannabis beverages (once it is federally legal in the US). 

Another attractive aspect of the merger is related to the amount of human capital that is associated with. Once the merger was completed, former Aphria CEO Irwin Simon took over as the CEO of the combined company. We are favorable on the experience that he has in regulated industries and will monitor how he continues to advance the business. 

A Global Cannabis Leader

Currently, Tilray’s production platform supports over 20 brands in over 20 countries. We believe the company has significant potential catalysts for growth and will monitor how the management team is able to execute on these opportunities. During the last two months, Tilray has been trending to the downside and the stock has fallen almost 40% from its June highs. 

Momentum has been trending lower for Tilray and we believe the business has a favorable risk-reward profile. Going forward, we believe the most significant potential catalysts for Tilray are:

  1. Federal legalization or decriminalization in the US
  2. Further capitalizing on the EU and capturing market share
  3. Increasing the types of CBD and THC products that are available to the consumer
  4. Lowering the average cost per gram by optimizing efficiencies across its global production platform   
  5. Increasing market share of Canada’s recreational and medical cannabis industry  

We believe that Tilray is executing on a multi-national expansion strategy and are bullish on the growth prospects that are associated with it. If you are interested in learning more about Tilray, please send an email to support@technical420.com with the subject “Tilray” to be added to our distribution list. 

For the fastest access to data on Tilray, sign up for our free newsletter!

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Technical420 newsletter.

 All good -- no spamming here.